Moreover, blockade of TIGIT or an anti-TIGIT antibody enhances T cell activation and restores CD8+ T exhaustion, enhancing antitumor activity in gastric cancer, colon cancer, myeloma, and head and neck squamous cell carcinoma [34–40]. This evidence concerns the gene CD8A and colonic neoplasm.